Role of interferons in the therapy of metastatic renal cell carcinoma.
The prognosis of metastatic renal cell carcinoma continues to be dismal because of the lack of effective systemic therapies. To date, existing chemotherapy and hormonal therapy have produced disappointing results. However, alpha interferon and other biologic response modifiers have recently shown evidence of modest but consistent activity. This review summarizes results obtained with alpha interferon alone or in combination in the treatment of advanced renal carcinoma. It is hoped that future development of this field of cancer therapy may result in further improvements in the clinical management of these patients.
Quesada
J R
JR
Oncology Center for I.V. Therapies and Cancer Therapeutics, Houston, Texas.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins